Pepinemab (VX15/2503)
Alzheimer's Disease (Early, MCI)
Key Facts
About Vaccinex
Vaccinex is a clinical-stage biotech focused on modulating the SEMA4D pathway to address significant unmet needs in oncology and neurodegenerative diseases. Its lead asset, pepinemab, has generated encouraging biomarker and clinical data in Alzheimer's and Huntington's disease, and is showing promise in combination immunotherapy for head and neck cancer. The company's strategy involves advancing its neurology programs toward pivotal trials, supported by a recent $60M financing for Alzheimer's, while exploring partnerships for its immuno-oncology assets and its versatile ACTIVMAb® discovery platform.
View full company profileAbout Vaccinex
Vaccinex is a clinical-stage biotech focused on modulating the SEMA4D pathway to address significant unmet needs in oncology and neurodegenerative diseases. Its lead asset, pepinemab, has generated encouraging biomarker and clinical data in Alzheimer's and Huntington's disease, and is showing promise in combination immunotherapy for head and neck cancer. The company's strategy involves advancing its neurology programs toward pivotal trials, supported by a recent $60M financing for Alzheimer's, while exploring partnerships for its immuno-oncology assets and its versatile ACTIVMAb® discovery platform.
View full company profileAbout Vaccinex
Vaccinex is a clinical-stage biotech focused on modulating the SEMA4D pathway to address significant unmet needs in oncology and neurodegenerative diseases. Its lead asset, pepinemab, has generated encouraging biomarker and clinical data in Alzheimer's and Huntington's disease, and is showing promise in combination immunotherapy for head and neck cancer. The company's strategy involves advancing its neurology programs toward pivotal trials, supported by a recent $60M financing for Alzheimer's, while exploring partnerships for its immuno-oncology assets and its versatile ACTIVMAb® discovery platform.
View full company profileAbout Vaccinex
Vaccinex is a clinical-stage biotech focused on modulating the SEMA4D pathway to address significant unmet needs in oncology and neurodegenerative diseases. Its lead asset, pepinemab, has generated encouraging biomarker and clinical data in Alzheimer's and Huntington's disease, and is showing promise in combination immunotherapy for head and neck cancer. The company's strategy involves advancing its neurology programs toward pivotal trials, supported by a recent $60M financing for Alzheimer's, while exploring partnerships for its immuno-oncology assets and its versatile ACTIVMAb® discovery platform.
View full company profile